{
    "root": "bc5ef851-e144-4d8e-8959-17d142945f4a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KENGREAL",
    "value": "20250521",
    "ingredients": [
        {
            "name": "CANGRELOR",
            "code": "6AQ1Y404U7",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_90841"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "kengreal indicated adjunct percutaneous coronary intervention ( pci ) reduce risk periprocedural myocardial infarction ( myocardial infarction ) , repeat coronary revascularization , stent thrombosis ( st ) patients treated p2y12 platelet inhibitor given glycoprotein iib/iiia inhibitor [ ( 14.1 ) ] .",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "kengreal intended via dedicated iv line , reconstitution dilution . ( 2.3 ) administer 30 mcg/kg intravenous ( iv ) bolus prior pci followed immediately 4 mcg/kg/min iv infusion least 2 hours duration procedure , whichever longer . ( 2.1 ) maintain platelet inhibition discontinuation kengreal infusion , administer oral p2y 12 platelet inhibitor . ( 2.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "kengreal supplied sterile lyophilized powder single-use 10 ml vials . ndc # 10122-620-01 : 10 ml vial containing 50 mg cangrelor ndc # 10122-620-10 : 10 count 10 ml vials containing 50 mg cangrelor vials kengreal stored usp controlled room temperature , [ 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) excursions 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) permitted ] . kengreal\u00ae registered trademeark chiesi farmaceutici s.p.a. distributed : chiesi usa , inc. cary , nc 27518 us-126-2-spl",
    "adverseReactions": "significant active bleeding ( 4.1 ) hypersensitivity kengreal component product ( 4.2 )",
    "indications_original": "KENGREAL is indicated as an adjunct\u00a0to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein\u00a0IIb/IIIa inhibitor [see Clinical \n                     Studies (\n                     \n                        14.1\n                     \n                     )].",
    "contraindications_original": "KENGREAL is intended for administration via a dedicated IV line, only after reconstitution and dilution. ( 2.3 ) Administer 30\u00a0mcg/kg intravenous (IV) bolus prior to PCI followed immediately by a 4\u00a0mcg/kg/min IV infusion for at least 2\u00a0hours or duration of procedure, whichever is longer. ( 2.1 ) To maintain platelet inhibition after discontinuation of KENGREAL infusion, administer an oral P2Y 12 platelet inhibitor. ( 2.2 )",
    "warningsAndPrecautions_original": "KENGREAL is supplied as a sterile lyophilized powder in single-use 10\u00a0mL vials.\n                  \n                     NDC # 10122-620-01: 10\u00a0mL vial containing 50\u00a0mg cangrelor\n                     NDC # 10122-620-10: 10\u00a0count of 10\u00a0mL vials containing 50\u00a0mg cangrelor\n                  \n                  Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) with excursions between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) permitted]. \n                  KENGREAL\u00ae is a registered trademeark of Chiesi Farmaceutici S.p.A.\n                  Distributed by:\nChiesi USA, Inc. \nCary, NC\u00a0 27518\n                  US-126-2-SPL",
    "adverseReactions_original": "Significant active bleeding ( 4.1 ) Hypersensitivity to KENGREAL or any component of the product ( 4.2 )",
    "drug": [
        {
            "name": "KENGREAL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_90841"
        }
    ]
}